← Human Trials & Peer-Reviewed Studies
A Mitochondrial Supplement Improves Function and Mitochondrial Activity in Autism: A Double-Blind Placebo-Controlled Cross-Over Trial.
Plain-language guide to PMID 40141123 (2025): double-blind randomized controlled trial of Copper (Supplement).
Key Facts
- PMID
- 40141123
- Journal
- International journal of molecular sciences
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Hill Z et al. (4 authors)
- DOI
- 10.3390/ijms26062479
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Copper (Supplement).
Mitochondrial respiration of peripheral blood mononuclear cell respiration, as measured by the Seahorse XFe96 (Agilent, Santa Clara, CA, USA) with the mitochondrial oxidative stress test, became more resilient to oxidative stress after the treatment, particularly in children with poor neurodevelopment.
Who Took Part
By PubMed's age tags, the people studied were children, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and crossover study.
The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.
Neither the participants nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the Copper (Supplement) group a baseline to be compared against.
Each person switched between Copper (Supplement) and the comparison at some point, usually with a gap in between.
Which product was received first was randomized.
What Was Measured
Mitochondrial respiration of peripheral blood mononuclear cell respiration, as measured by the Seahorse XFe96 (Agilent, Santa Clara, CA, USA) with the mitochondrial oxidative stress test, became more resilient to oxidative stress after the treatment, particularly in children with poor neurodevelopment.
Topics PubMed links to this paper include Mitochondria, Dietary Supplements, Autism Spectrum Disorder, Autistic Disorder and Oxidative Stress.
Author keywords: clinical trial, nutritional supplement and respirometry.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).
The publication is from 2025 (International journal of molecular sciences), a journal based in Switzerland.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.